Intel leads $20M funding round for AI-powered medication management company

Intel Capital, the venture capital arm of tech giant Intel, led a $20 million funding round for MDI Health, an artificial intelligence-powered medication management company.

Advertisement

MDI’s platform analyzes different factors to identify medication-related risks. The financing brings the company’s total funding to $26 million, according to a Feb. 14 MDI Health news release.

The company will use the financing to scale its product in the U.S. and Israel.

“With more patients and less staff, clinicians’ mission to deliver exceptional care has limitations. Clinicians are forced to make a judgment call when treating patients, leading to unnecessary medications, clinic visits, hospitalizations, and readmissions,” Intel Capital Managing Director Roi Bar-Kat said in the release. “MDI Health’s technology is a game changer for health plans and value-based providers, helping them deliver ‘whole’ person medication management, at scale — saving costs, and most importantly saving patients’ lives.”

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

What clinicians need from AI after the pilot: Lessons from Adventist Health and Rady Children’s

Friday, July 24
12:00 PM - 1:00 PM CDT

Presenters: Dr. Dieter Sumerauer, Rady Children’s HealthDr. Salman Naqvi, AdventistDr. Reid Conant, Abridge

Advertisement

Next Up in Innovation

Advertisement

Comments are closed.